Understanding HER2-Positive Breast Cancer
HER2 (Human Epidermal Growth Factor Receptor 2) is a protein on breast cancer cells that drives aggressive growth. HER2-positive cancers are defined by HER2 overexpression (IHC 3+) or amplification (FISH positive).
Clinical significance: HER2-positive breast cancers historically had poor prognosis (~30% 5-year survival untreated). Trastuzumab (Herceptin), approved in 1998, transformed outcomes — now median survival for metastatic HER2+ disease exceeds 5 years with modern dual anti-HER2 therapy.
Standard treatment:
- Early-stage (adjuvant): Chemotherapy + trastuzumab ± pertuzumab for 1 year. Newer trials test combining with novel agents (e.g., tyrosine kinase inhibitors, anti-HER2 bispecific antibodies).
- Metastatic: Dual anti-HER2 therapy (trastuzumab + pertuzumab) + chemotherapy. T-DM1 (antibody-drug conjugate) for prior therapy. Novel agents (margetuximab, tucatinib, zanidatamab) in development.
HER2 Testing and Assessment
HER2 status is determined by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH):
HER2-Positive Subtypes and Treatment Strategy
HER2-enriched subtype: Genomic classification showing high HER2 expression, usually ER/PR-negative. Highly responsive to anti-HER2 therapy. May also express immune checkpoint ligands (PD-L1), qualifying for combination immunotherapy + anti-HER2 trials.
Hormone receptor coexpression: ~30-40% of HER2+ breast cancers are also ER+ or PR+. These may benefit from combined endocrine therapy + anti-HER2 therapy (e.g., trastuzumab + letrozole). Trials often stratify by HR status.
Resistance mechanisms: After trastuzumab progression, resistance may involve HER3 activation, PI3K pathway mutations, or immune evasion. New trials target these mechanisms with combinations (tucatinib + trastuzumab, margetuximab, bispecific antibodies targeting HER2 × HER3).
Ready to explore HER2-positive trials matching your profile?
Upload your pathology report, treatment history, and imaging. We'll match you to recruiting trials and explain your eligibility for each.
HER2-Positive Breast Cancer & Trials
HER2-positive means your cancer cells have extra copies of the HER2 gene or overexpress the HER2 protein. This drives aggressive tumor growth but makes your cancer highly sensitive to anti-HER2 therapies like trastuzumab (Herceptin).
Historically, HER2+ breast cancer had the worst prognosis among breast cancer subtypes. Since 1998, when trastuzumab was approved, outcomes have dramatically improved — HER2+ disease now often has survival similar to hormone-receptor-positive disease when treated with dual anti-HER2 blockade.
After trastuzumab progression, multiple trial options exist:
Dual anti-HER2 blockade: If you haven't received it, trastuzumab + pertuzumab is standard. If you have, consider alternative dual combinations being tested in trials.
T-DM1 (Kadcyla): Antibody-drug conjugate combining trastuzumab with chemotherapy payload. Highly effective after trastuzumab progression and increasingly tested in combinations.
Novel anti-HER2 agents: Tucatinib (oral tyrosine kinase inhibitor), margetuximab (Fc-engineered trastuzumab), zanidatamab (bispecific targeting HER2 × HER2), and other next-generation agents in trials.
HER3-targeted therapy: HER3 activation is a common resistance mechanism. Patritumab (HER3 antibody) in combination trials.
Yes. While HER2 is the primary driving mutation, additional testing helps identify other trial opportunities:
Hormone receptors (ER/PR): If coexpressed, trials may combine anti-HER2 + endocrine therapy.
PD-L1 expression: Emerging data suggest HER2+ cancers with high PD-L1 benefit from checkpoint immunotherapy combined with anti-HER2 therapy. Increasingly tested in trials.
Comprehensive genomic profiling: May reveal PI3K, TP53, BRCA mutations that predict response to specific trial combinations.
Yes — a major shift in HER2+ trials. HER2-low breast cancers (IHC 1+ or 2+/FISH-) historically weren't treated with anti-HER2 therapy. New trials show novel anti-HER2 agents (sacituzumab govitecan, combining anti-HER2 with chemotherapy payload) are effective in HER2-low disease.
If your tumor is HER2-low, you now qualify for trials previously restricted to HER2+ patients. This is an emerging area with rapidly expanding options.
Sometimes. Many HER2+ trials exclude untreated brain metastases, but several options exist:
CNS-penetrating agents: Tucatinib (oral tyrosine kinase inhibitor) penetrates the blood-brain barrier better than monoclonal antibodies. Trials combining tucatinib + trastuzumab specifically enroll patients with brain involvement.
After local treatment: If you've had brain radiation or surgery and the brain disease is controlled, you may qualify for systemic HER2+ trials.
Discuss your specific brain involvement with your neuro-oncologist or medical oncologist — it determines which trials are appropriate.
Typically:
(1) Pathology report confirming HER2 status (IHC and FISH results). Include hormone receptor status (ER/PR).
(2) Imaging reports (CT, MRI, bone scan) showing current disease extent and any metastases.
(3) Prior treatment history with dates, agents, and response (complete response, partial response, stable disease, or progressive disease).
(4) ECOG performance status from your oncologist (0-2 scale).
(5) Recent blood work (CBC, liver/kidney function, cardiac assessment — important for cardiotoxicity monitoring with anti-HER2 therapy).